Fnx Performance products are intended strictly for qualified in vitro laboratory research. For Research Use Only. Not for human or animal consumption. Not for compounding or therapeutic application.
Explore mechanism data, evidence tiers, safety, and regulatory context for every compound in the Fnx catalog. Each peptide has its own research profile, filter by category or follow a tag from any product page.
FDA approved with randomized controlled trials behind the approved use.
A large or maturing human RCT base, but not (yet) FDA approved for this use.
Registered and used abroad (e.g. Russia) on modest, mostly single institution trials.
A plausible mechanism, but human efficacy for the marketed use is unproven.
Animal/in vitro data and anecdote only, little to no human evidence and real safety unknowns.
A stabilized synthetic analog of GHRH(1-44) that resists DPP-IV degradation, FDA approved to reduce excess visceral abdominal fat in HIV associated lipodystrophy.
A GHRH analog paired with a selective ghrelin receptor agonist, combined to synergistically stimulate pulsatile growth hormone release.
A once weekly triple agonist of the GLP-1, GIP, and glucagon receptors, the glucagon arm distinguishing it from dual agonists by raising energy expenditure.
A modified C terminal fragment of growth hormone (176-191) intended to isolate GH's fat burning action without raising IGF-1 or affecting blood glucose.